Melinta revises bid for Tetraphase

Melinta has revised their bid for Tetraphase to $34M in cash plus $16M payable under a CVR, beating out AcelRx’s newly revised bid from yesterday of $30M in cash and a $14.5 payable.



“The Tetraphase Board has not changed its recommendation with respect to the pending transaction with AcelRx, and the Tetraphase Board continues to recommend the AcelRx Merger Agreement to its stockholders...and is not making any recommendation with respect to the Melinta.”
Businesswire

This statement was issued yesterday however since the issuance of the statement, the Tetraphase board has determined the revised Melinta bid is superior to AcelRx's latest bid.

The_MergerSight_Group_Instagram
The_MergerSight_Group_LinkedIn
The_MergerSight_Group_Facebook

© 2018 - 2020 The MergerSight Group

Subscribe to Newsletter